These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 11017044

  • 1. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.
    Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD, Sebti SM.
    Nat Biotechnol; 2000 Oct; 18(10):1065-70. PubMed ID: 11017044
    [Abstract] [Full Text] [Related]

  • 2. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.
    Cancer Res; 2000 Apr 15; 60(8):2178-89. PubMed ID: 10786682
    [Abstract] [Full Text] [Related]

  • 3. Design of growth factor antagonists with antiangiogenic and antitumor properties.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6566-73. PubMed ID: 11426641
    [Abstract] [Full Text] [Related]

  • 4. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors.
    Sun J, Wang DA, Jain RK, Carie A, Paquette S, Ennis E, Blaskovich MA, Baldini L, Coppola D, Hamilton AD, Sebti SM.
    Oncogene; 2005 Jul 07; 24(29):4701-9. PubMed ID: 15897913
    [Abstract] [Full Text] [Related]

  • 5. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ.
    Clin Cancer Res; 2000 Mar 07; 6(3):957-65. PubMed ID: 10741721
    [Abstract] [Full Text] [Related]

  • 6. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.
    Cancer Res; 2004 May 15; 64(10):3586-92. PubMed ID: 15150116
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM.
    Medicina (B Aires); 2000 May 15; 60 Suppl 2():41-7. PubMed ID: 11188930
    [Abstract] [Full Text] [Related]

  • 8. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington.
    Cancer Res; 2000 Aug 01; 60(15):4152-60. PubMed ID: 10945623
    [Abstract] [Full Text] [Related]

  • 9. Flk-1 as a target for tumor growth inhibition.
    Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK.
    Cancer Res; 1996 Aug 01; 56(15):3540-5. PubMed ID: 8758924
    [Abstract] [Full Text] [Related]

  • 10. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H, Jezequel S, Löhr M, Shaikh S, Davis D, Soker S, Selwood D, Zachary I.
    Biochem Biophys Res Commun; 2001 Apr 27; 283(1):164-73. PubMed ID: 11322784
    [Abstract] [Full Text] [Related]

  • 11. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
    Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM.
    Clin Cancer Res; 2000 Dec 27; 6(12):4848-58. PubMed ID: 11156244
    [Abstract] [Full Text] [Related]

  • 12. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE.
    Cancer Res; 2000 Sep 15; 60(18):5117-24. PubMed ID: 11016638
    [Abstract] [Full Text] [Related]

  • 13. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 14. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.
    Clin Cancer Res; 2002 Apr 15; 8(4):1242-50. PubMed ID: 11948139
    [Abstract] [Full Text] [Related]

  • 15. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 17. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
    Kovalenko M, Gazit A, Böhmer A, Rorsman C, Rönnstrand L, Heldin CH, Waltenberger J, Böhmer FD, Levitzki A.
    Cancer Res; 1994 Dec 01; 54(23):6106-14. PubMed ID: 7954456
    [Abstract] [Full Text] [Related]

  • 18. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D, Williams JI, Pietras RJ.
    Oncogene; 2002 Apr 25; 21(18):2805-14. PubMed ID: 11973639
    [Abstract] [Full Text] [Related]

  • 19. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z.
    Cancer Res; 2001 Oct 01; 61(19):7002-8. PubMed ID: 11585724
    [Abstract] [Full Text] [Related]

  • 20. VEGF is major stimulator in model of choroidal neovascularization.
    Kwak N, Okamoto N, Wood JM, Campochiaro PA.
    Invest Ophthalmol Vis Sci; 2000 Sep 01; 41(10):3158-64. PubMed ID: 10967078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.